Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial NCT05778877 evaluating SEL-302 in pediatric patients with methylmalonic acidemia has been withdrawn, with no further enrollment planned.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methylmalonic Acidemia

Drugs mentioned

• SEL-302

Snippet

Sponsor: Selecta Biosciences, Inc. | Conditions: Methylmalonic Acidemia (MMA) | Phase 1, Phase 2 | Status: WITHDRAWN